why choose us

Clinical Trials Search

Showing 3,790 of 132,656 result(s)
Food Swaps to Improve the Healthfulness and Reduce the Carbon Footprint of Grocery Purchases

Status: COMPLETED

Condition: Food Selection

Interventions: Participants will view "health grade" labels on all products in the online grocery store indicating their healthfulness as estimated by Unit

Date: 2024-10-16

Smart Nutrition, Healthier Communities

Status: COMPLETED

Condition: Obesity and Overweight

Interventions: Behavioral intervention for lifestyle change

Date: 2024-10-15

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

Status: COMPLETED

Condition: Asthma

Interventions: Drug Treatment: (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007) Randomized participants will receive a single-dose (2 inhalations)

Date: 2024-10-15

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

Status: COMPLETED

Condition: Asthma

Interventions: Drug Treatment: (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007) Randomized participants will receive a single-dose (2 inhalations)

Date: 2024-10-15

Photoplethysmography Signal Differences Between Heart Failure Patients and Healthy Population

Status: COMPLETED

Condition: Heart Failure

Interventions:

PPG signal will be measured on CE certified medical devices.
Two measurements will be performed - standing and in the recumbent position using

Date: 2024-10-15

A Study of [14C]-LY3866288 in Healthy Participants

Status: COMPLETED

Condition: Healthy

Interventions: Administered orally.

Date: 2024-10-15

CT Indices Analysis in ICU Pneumonia Patients With Acute Respiratory Failure (CT:Computed Tomography, ICU: Intensive Care Unit)

Status: COMPLETED

Condition: Acute Respiratory Failure

Interventions:

Date: 2024-10-15

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

Status: COMPLETED

Condition: IgA Nephropathy (IgAN)

Interventions: DRUG: Placebo - QD or BID, 24-weeks fixed dose.
DRUG: HSK39297 50mgBID - 24-weeks fixed dose.
DRUG: HSK39297 100mgBID - 24-weeks fixed dose.

Date: 2024-10-15